Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal
-
ナレーター：
-
著者：
In this episode I am joined by Kate Haviland, who most recently served as President and CEO of Blueprint Medicines, guiding it from a clinical-stage company through a fully integrated commercial business and ultimately through its roughly $9.5 billion acquisition by Sanofi in 2025. Over a more than twenty-year career spanning Genzyme, PTC Therapeutics, Sarepta, Idera, and Blueprint, Kate has built a reputation for bridging rigorous science with sharp business instincts, equally fluent in the lab and the boardroom. She studied biochemistry and economics at Wesleyan, earned her MBA at Harvard Business School, and today serves as Board Chair of both Fulcrum Therapeutics and GC Therapeutics, as a director at Bicara and Avalyn, and on the board of BIO. This episode was recorded in 2025